Extended HPV genotyping and dual stain for the triage of primary HPV screen‐positive cases: Practical guidance for the cytopathology laboratory
Cancer Cytopathology · 2025
DOI: 10.1002/cncy.70006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cytopathology, 2025. Verfasst von Robert A Goulart und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Massachusetts Memorial Health and University of Massachusetts Chan Medical School, Worcester, Massachusetts, U…. Hauptthemen laut MEDLINE: Triage, Papillomavirus Infections, Uterine Cervical Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
Because of many factors, the landscape of cervical cancer prevention is again at a pivot point within the United States. Primary human papillomavirus (HPV) screening has been recommended as the preferred testing method by the American Cancer Society since 2020. Although primary HPV testing provides high negative predictive value in screening, women who screen positive for HPV need triage using methods that have an optimal balance between sensitivity for precancer and the number of colposcopies required for detection. The triage test ideally should maximize specificity while also reassuring patients who test negative, although it should be acknowledged that no screening or triage test can entirely exclude disease in a screen‐positive patient. While cervical cytology (the Papanicolaou test) triage of primary HPV screen‐positive patients is currently recommended by most screening strategies, additional triage tests, specifically extended HPV genotyping and combined p16/Ki‐67 dual‐stain immunocytochemistry, are now approved by the US Food and Drug Administration and incorporated into cervical cancer screening and management guidelines. Incorporating these triage methods into practice should be achieved by using appropriate validation/verification and implementation steps and, in the case of dual‐stain immunocytochemistry, appropriate cytologist/cytopathologist training. The US Food and Drug Administration approval of vaginal self‐collection in May 2024 is another significant advance for increasing access to screening. These samples can only be tested using primary HPV screening platforms, and guidance for management has been endorsed by the ASCCP's enduring guidelines process. This review discusses issues that warrant consideration before implementation and provides practical guidance for the incorporation of self‐collected specimens and extended genotyping/dual‐stain tests into the workflow of the cytopathology laboratory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, University of Massachusetts Memorial Health and University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- The Permanente Medical Group, Kaiser Permanente Regional Laboratory, Berkeley, California, USA.
- Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
- Department of Pathology, University of Virginia Health, Charlottesville, Virginia, USA.
ORCID-Profile: Robert A Goulart
Zitieren
APA
Goulart, R. A., Nayar, R., Lorey, T., Joste, N., & Stoler, M. H. (2025). Extended HPV genotyping and dual stain for the triage of primary HPV screen‐positive cases: Practical guidance for the cytopathology laboratory. Cancer Cytopathology. https://doi.org/10.1002/cncy.70006
Vancouver
Goulart RA, Nayar R, Lorey T, Joste N, Stoler MH. Extended HPV genotyping and dual stain for the triage of primary HPV screen‐positive cases: Practical guidance for the cytopathology laboratory. Cancer Cytopathology. 2025. doi:10.1002/cncy.70006
BibTeX
@article{Goulart2025,
author = {Goulart, Robert A and Nayar, Ritu and Lorey, Thomas and Joste, Nancy and Stoler, Mark H},
title = {Extended HPV genotyping and dual stain for the triage of primary HPV screen‐positive cases: Practical guidance for the cytopathology laboratory},
journal = {Cancer Cytopathology},
year = {2025},
doi = {10.1002/cncy.70006}
}
EUVIMED